Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov10310.25208/0042-4609-2015-91-1-41-45EDITORIALРедакционная статьяSystemic therapy of androgenic alopeciaСистемная терапия больных андрогенетической алопециейKondrakhinaI. N.КондрахинаИ. Н.
Russian Federation
MareevaA. N.МарееваА. Н.
Russian Federation
nastasya_66@mail.ruState Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России24022015911414524082017Copyright ©; 2015, Kondrakhina I.N., Mareeva A.N.Copyright ©; 2015, Кондрахина И.Н., Мареева А.Н.2015Kondrakhina I.N., Mareeva A.N.Кондрахина И.Н., Мареева А.Н.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/103

The article describes the literature sources related to the efficacy of systemic therapy of androgenic alopecia in female and male.

Представлены данные литературы по эффективности применения системной терапии в лечении андрогенной алопеции у женщин и мужчин

андрогенная алопециятерапия алопецииandrogenic alopeciatherapy of androgenic alopeciaTosti A., Piraccini B., Sisti A. et al. Hair loss in women. Minerva Ginecol 2009; 61: 445-452.Kelekci K.H, Kelekci S. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. J Dermatolog Treat. 2012 Jun; 23 (3): 177-83.Vexiau P., Chaspoux C., Boudou P. et al. Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: A controlled, 12-month randomized trial. Br J Dermatol 146: 992-999, 2002.Brzezinska-Wcislo L. Assessment of efficacy of Diane-35 in androgenetic feminine alopecia. Wiad Lek, 2003. 56: 202-5.Lucky A.W., Piacquadio D.J., Ditre C.M. et al. A randomized, placebocontrolled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol, 2004, 50: 541-53.Алейникова Н.Л., Мазитова Л.П., Чернуха Г.Е. Сравнительная эффективность антиандрогенных препаратов в лечении андрогенетической алопеции женщин репродуктивного возраста. Экспериментальная и клиническая дерматокосметология 2004; 6: 38-40.Мареева А.Н. Оптимизация тактики ведения женщин репродуктивного возраста с андрогенетической алопецией с учетом уровня стероидных гормонов и молекулярно-генетических факторов. Автореферат диссертации на соискание ученой степени кандидата медицинских наук. М. 2013.Sinclair R., Wewerinke M., Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol, 2005, 152: 466-73.Rathnayake D., Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010 Jul; 28 (3): 611-8.Carmina E., Lobo N. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003, 79: 91-5.Paradisi R., Porcu E., Fabbri R. et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011 Apr; 45 (4): 469-75.Ong K., F. de Zegher, López-Bermejo A. et al. Flutamide-metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype. European Journal of Endocrinology, 2007: Vol. 157, Issue 5: 661-668.Kaufman K.D., Olsen E.A., Whiting D. et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol, 1998, 39: 578-89.Price V.H., Roberts J.L., Hordinsky M. et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768-76.Shum K.W., Cullen D.R., Messenger A.G. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 2002; 47: 733-9.Thai K.E., Sinclair R.D. Finasteride for female androgenetic alopecia. Br J Dermatol 2002; 147: 812-13.Trüeb R.M. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004, 209: 202-7.Oliveira-Soares R., Maia e Silva J., Peres Correia M. Finasteride 5 mg/day reatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women. Int J Trichology. 2013 Jan-Mar; 5 (1): 22-25.Boersma I.H., Oranje A.P., Grimalt R. et al. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014 Nov-Dec; 80 (6): 521-5.Vexiau P., Chaspoux C., Boudou P. et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res. 2000 Dec; 292 (12): 598-604.Shapiro J., Kaufman K.D. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Invest Derm Symp Proc 2003: 8: 20-23.Kaufman K.D., Girman C.J., Round E.M. et al. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol 2008: 18: 407-411.Kaufman K.D, Rotonda J., Shah A.K. et al. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol 2008: 18: 400-406.Olsen E.A., Hordinsky M., Whiting D. et al. Dutasteride Alopecis Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006: 55: 1014-1023.Eun H.C., Kwon O.S., Yeon J.H. et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebocontrolled, phase III study. J Am Acad Dermatol. 2010 Aug; 63 (2): 252-8.Gubelin Harcha W., Barboza Martinez J., Tsai T.F. et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014 Mar; 70 (3): 489-498.Jung J.Y., Yeon J.H., Choi J.W. et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014 Nov; 53 (11): 1351-7.